Pembrolizumab, Ibrutinib and Rituximab in PCNSL

This research study is evaluating a combination therapy of 3 drugs as possible treatments for recurrent primary central nervous system lymphoma (PCNSL). The three drugs being used in the study are: * Pembrolizumab (MK3475) * Ibrutinib * Rituximab (or biosimilar)

Trial Details

NCT ID
NCT04421560
Phase
PHASE1 / PHASE2
Sponsor
Dana-Farber Cancer Institute
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • Ibrutinib
  • Pembrolizumab
  • Rituximab
Locations (sample)
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • New York, New York, United States|40.71427,-74.00597
  • New York, New York, United States|40.71427,-74.00597

Key Eligibility Criteria

  • Participant must be able to understand and willing to sign a written informed consent document.
  • Participant must have signed and dated an IRB/IEC approved written informed consent form in accordance with regulatory and institutional guidelines…
  • Participant must be willing and able to comply with scheduled visits, treatment schedule, laboratory tests, and other requirements of the study.
  • Participant must be at least 18 years old on day of signing informed consent.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →